IP Library Granted Patent US 7,053,202
Granted Patent B2
US 7,053,202 · App. 10/272,899 · Granted May 30, 2006

Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,053,202
App. No.
10/272,899
Granted
May 30, 2006
Kind
B2
Abstract

Featured are DNA molecules, expression vectors, and host cells useful for creation of immunoglobulins, as well as novel immunoglobulin molecules termed monobodies. Additionally provided are methods of production of immunoglobulins, including monobodies, as well as methods of using the disclosed immunoglobulin and monobody constructs, expression vectors and host cells containing DNA encoding molecules for production of immunoglobulin and monobody proteins.

Claims (37)

1. A DNA expression vector comprising a nucleic acid sequence encoding a human IgG1 heavy chain constant region sequence of SEQ ID NO: 10, and a nucleic acid sequence encoding a humanized 1D9 heavy chain variable region.

2. The expression vector of claim 1 , further comprising a nucleic acid sequence encoding a human light chain constant region.

3. The expression vector of claim 2 , wherein the human light chain constant region is a kappa light chain constant region.

4. The expression vector of claim 1 , further comprising a nucleic acid sequence encoding a humanized 1D9 light chain variable region.

5. The expression vector of claim 4 , further comprising a nucleic acid sequence encoding a human light chain constant region.

6. The expression vector of claim 5 , wherein the human light chain constant region is a kappa light chain constant region.

7. The expression vector of claim 1 , wherein the nucleic acid sequence comprises the heavy chain constant region encoding nucleotide sequence of SEQ ID NO: 9.

8. The expression vector of claim 3 or claim 6 , wherein the nucleic acid sequence encodes the light chain constant region sequence of SEQ ID NO: 12.

9. The expression vector of claim 8 , wherein the nucleic acid sequence comprises the light chain constant region encoding nucleotide sequence of SEQ ID NO: 11.

10. The expression vector of claim 1 , wherein the nucleic acid sequence encoding the heavy chain constant region and the nucleic acid encoding the humanized heavy chain variable region are operably linked to a promoter selected from the group consisting of a EF-1a promoter, a CMV promoter, an SV40 promoter, and an adenovirus major late promoter.

11. The expression vector of claim 10 , wherein the promoter is a EF-1a promoter.

12. The expression vector of claim 11 , wherein the nucleic acid sequence encoding the heavy chain constant region and the nucleic acid sequence encoding the humanized heavy chain variable region are under control of the same promoter.

13. The expression vector of claim 11 or claim 12 , wherein the vector further comprises a BGH poly A sequence.

14. The expression vector of claim 13 , wherein the BGH polyA sequence is downstream from the sequence encoding the heavy chain constant region.

15. The expression vector of claim 1 , further comprising a selectable marker gene.

16. The expression vector of claim 15 , wherein the selectable marker gene is selected from the group consisting of a dihydrofolate reductase (DHFR) gene and a neo gene.

17. The expression vector of claim 1 , wherein the expression vector comprises at least two marker genes and the marker genes are a DHFR gene and a neo gene.

18. The expression vector of claim 1 , wherein the nucleic acid sequence encoding the heavy chain constant region further comprises an immunoglobulin leader sequence.

19. The expression vector of claim 3 or claim 6 , wherein the nucleic acid sequence encoding the light chain constant region further comprises an immunoglobulin leader sequence.

20. The expression vector of claim 1 , wherein the nucleic acid sequence encoding the humanized heavy chain variable region further comprises an immunoglobulin leader sequence.

21. The expression vector of claim 4 or claim 6 , wherein the nucleic acid sequence encoding the humanized light chain variable region further comprises an immunoglobulin leader sequence.

22. A DNA expression vector comprising a nucleic acid sequence encoding the heavy chain constant region sequence of SEQ ID NO: 10, a nucleic acid sequence encoding a humanized 1D9 heavy chain variable region, a nucleic acid encoding the light chain constant region sequence of SEQ ID NO: 12, and a nucleic acid sequence encoding a humanized 1D9 light chain variable region.

23. The expression vector of claim 22 , wherein the nucleic acid sequence encoding the heavy chain constant region and the nucleic acid sequence encoding the humanized heavy chain variable region are operably linked to an EF-1a promoter.

24. The expression vector of claim 22 , wherein the nucleic acid sequence encoding the light chain constant region and the nucleic acid sequence encoding the humanized light chain variable region are operably linked to an EF-1a promoter.

25. The expression vector of claim 23 , wherein the nucleic acid sequence encoding the light chain constant region and the nucleic acid sequence encoding the humanized light chain variable region are operably linked to an EF-1a promoter.

26. The expression vector of claim 22 , claim 23 , claim 24 or claim 25 , wherein the vector further comprises a BGH poly A sequence.

27. The expression vector of claim 26 , wherein the BGH polyA sequence is downstream from the sequence encoding the heavy chain constant region.

28. The expression vector of claim 22 , further comprising a selectable marker gene.

29. The expression vector of claim 28 , wherein the selectable marker is selected from the group consisting of a DHFR gene and a neo gene.

30. The expression vector of claim 22 , wherein the nucleic acid encoding the humanized heavy chain variable region further comprises an immunoglobulin leader sequence.

31. The expression vector of claim 22 , wherein the nucleic acid sequence encoding the humanized light chain variable region further comprises an immunoglobulin leader sequence.

32. A host cell comprising the expression vector of claim 1 or claim 22 .

33. The cell of claim 32 , wherein the cell is selected from the group consisting of a bacterial, a yeast and a mammalian cell.

34. The cell of claim 33 , wherein the cell is a mammalian cell.

35. The cell of claim 34 , wherein the mammalian cell is selected from the group consisting of a lymphocytic cell line, CHO, and COS cells.

36. The cell of claim 34 , wherein the mammalian cell is a CHO cell.

37. The cell of claim 36 , wherein the CHO cell is a DHFR deficient CHO cell.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2021
From: MILLENNIUM PHARMACEUTICALS, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 056729/0503 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 15, 2003
From: O'KEEFE, THERESA L.; HEALEY, JUDITH JACQUES; NEWMAN, WALTER; PONATH, PAUL D.; KEYT, BRUCE A.
To: MILLENNIUM PHARMACEUTICALS, INC.
Reel/Frame 013948/0350 →